Table of Contents
Sexual Health Market Overview
Sexual health is vital for overall well-being. It involves practicing safe sex through methods like condom use and regular STI screenings.
Contraception options should be understood to prevent unintended pregnancies. Open communication with sexual partners fosters healthy relationships and ensures mutual consent.
Self-care, including genital hygiene and addressing any discomfort, is essential. Mental and emotional well-being also play a crucial role, with factors like stress and trauma impacting sexual health.
Accessing reliable information and respecting diversity in sexual orientation and gender identity are key to promoting inclusivity and addressing individual needs.
Market Drivers
Global sexual health market growth is driven by heightened awareness and educational efforts combating STIs and preventing unintended pregnancies through improved healthcare access.
Rising demand for contraceptives, including condoms and hormonal options, contributes to this expansion.
Technological advancements, such as long-acting reversible contraceptives and topical gels for STI prevention, also fuel market growth.
Escalating STI prevalence underscores the need for effective prevention and treatment, further stimulating the market.
Increased investments in sexual health research, supported by government initiatives, propel market growth.
Market Size
- The global sexual wellness market surpassed $26 billion in 2017 and is projected to reach around $37.2 billion by 2023.
- Sexually Transmitted Disease Market Size is expected to be worth around USD 171 Bn by 2032 from USD 95 Bn in 2022, growing at a CAGR of 6.17% during the forecast period from 2022 to 2032.
List of Major Companies
These are the top ten companies operating in the Sexual Health Market:
Abbott
Company Overview
| Establishment Year | 1888 |
| Headquarter | Green Oaks, Illinois, U.S. |
| Key Management | Robert B. Ford (Chairman & CEO) |
| Revenue (US$ Bn) | $ 40.1 Billion (2023) |
| Headcount | ~ 114,000 (2023) |
| Website | http://abbott.com/ |
About Abbott Laboratories
Abbott Laboratories is a key player in sexual health, specializing in diagnostics and treatments for STIs. Their Alinity m STI assay has transformed STI testing by detecting multiple infections in one sample, streamlining testing processes.
Recent developments show Abbott’s focus on expanding its diagnostics range and improving lab efficiency, with steady growth reported in the diagnostics segment despite COVID-19 challenges.
The company is exploring home-based testing solutions to meet the demand for convenient sexual health services.
Financial reports highlight Abbott’s commitment to organic growth and innovation, demonstrating their dedication to improving sexual health worldwide.
Geographical Presence
Abbott Laboratories, headquartered in Illinois, USA, boasts a strong global presence with operations spanning across North America, Europe, Asia-Pacific, and Latin America.
In North America, it maintains key facilities and offices across various states, while in Europe, it has established strategic hubs in countries like Germany and the United Kingdom.
Expanding into the Asia-Pacific region, Abbott has positioned itself in countries such as China and Japan to address emerging healthcare needs.
Additionally, it has a notable presence in Latin America, with operations in Brazil and Mexico. This expansive footprint underscores Abbott’s commitment to delivering innovative healthcare solutions worldwide.
Recent Developments
- In April 2024, the FDA approved Abbott’s i-STAT TBI cartridge for whole blood use, allowing quick bedside assessment and lab-quality results in just 15 minutes for suspected concussions.
- In January 2024, Abbott introduced its new PROTALITY™ brand, starting with a high-protein nutrition shake. It’s the inaugural product in the line, catering to adults aiming for weight loss while preserving muscle mass and overall nutrition.
Merck
Company Overview
| Establishment Year | 1891 |
| Headquarter | Rahway, New Jersey, U.S. |
| Key Management | Robert M. Davis (Chairman, President and CEO) |
| Revenue (US$ Bn) | $ 60.1 B (2023) |
| Headcount | ~ 72,000 (2023) |
| Website | http://merck.com/ |
About Merck
Merck & Co., Inc. is a significant player in the sexual health sector, concentrating on treatments for sexually transmitted infections (STIs) and HPV-related diseases.
Notably, its HPV vaccine, Gardasil, has been instrumental in preventing HPV-related cancers. Through strategic acquisitions like Harpoon Therapeutics in 2024, Merck has bolstered its oncology pipeline, targeting advanced cancers often linked with HPV.
This expansion aligns with Merck’s strategy to diversify and fortify its portfolio in oncology and sexual health.
The company’s ongoing research aims to improve the efficacy and accessibility of its sexual health products, complemented by its active participation in major healthcare conferences and dedication to expanding maternal care worldwide.
Geographical Presence
Merck has a strong global presence spanning North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.
In North America, especially the U.S., Merck is engaged in research, manufacturing, and distribution. In Europe, covering the UK, Germany, France, and Italy, it participates in diverse research and commercial endeavors.
Across the Asia-Pacific region, including China, Japan, India, and Australia, Merck focuses on expanding its product portfolio and market reach.
Similarly, in Latin America, Merck operates in Brazil, Mexico, Argentina, and Colombia and strives to enhance healthcare accessibility.
Additionally, in the Middle East and Africa, Merck collaborates with local partners to address healthcare challenges. Overall, Merck’s global presence highlights its dedication to advancing healthcare worldwide.
Recent Developments
- In March 2024, Merck acquired Harpoon Therapeutics, Inc., making it a fully-owned subsidiary.
- In June 2022, Merck launched the Merck Digital Sciences Studio (MDSS) to drive innovation in drug discovery and development using technology.
Sanofi
Company Overview
| Establishment Year | 1973 |
| Headquarter | Paris, France |
| Key Management | Paul Hudson (CEO) |
| Revenue (US$ Bn) | $ 50.2 Billion (2022) |
| Headcount | ~ 86,088 (2023) |
| Website | http://sanofi.com/ |
About Sanofi
Sanofi S.A. is a key player in sexual health, prioritizing innovative treatments and expanding its product range through strategic partnerships and acquisitions.
Notably, Sanofi has recently launched new molecular entities and expanded its immunology pipeline. Its “Play to Win” strategy involves cost-saving measures and increased R&D investments for sustained growth.
Sanofi plans to separate its Consumer Healthcare business to concentrate on innovative medicines and vaccines.
Furthermore, it has bolstered its pipeline with over 25 value-driven M&A deals, reinforcing its position in the healthcare market.
Geographical Presence
Sanofi, based in Paris, operates globally across 100+ countries spanning North America, Europe, Asia-Pacific, Latin America, Africa, and the Middle East.
In North America, it conducts research, manufacturing, and sales in the US and Canada. Across Europe, Sanofi is prominent in France, Germany, and the UK, offering diverse pharmaceuticals and healthcare products.
It aims for growth in the Asia-Pacific, focusing on China, Japan, and India. In Latin America, Africa, and the Middle East, Sanofi collaborates locally to improve healthcare accessibility. Overall, Sanofi’s global presence reflects its commitment to innovative healthcare solutions.
Recent Development
- In May 2024, Sanofi, Formation Bio, and OpenAI teamed up to create AI-driven software to speed up drug development and deliver medicines to patients faster.
- In October 2023, Sanofi updated its “Play to Win” strategy, emphasizing its core objectives: launching transformative medicines and vaccines, optimizing resource allocation, and improving R&D efficiency.
Thermo-Fisher
Company Overview
| Establishment Year | 1958 |
| Headquarter | Waltham, Massachusetts, U.S. |
| Key Management | Marc N. Casper (CEO) |
| Revenue (US$ Bn) | $ 42.8 Billion (2023) |
| Headcount | ~ 122,000 (2023) |
| Website | http://www.thermofisher.com/ |
About Thermo Fisher Scientific
Thermo Fisher Scientific is a key player in sexual health diagnostics, offering advanced solutions for detecting sexually transmitted infections (STIs).
Their product lineup, like the Applied Biosystems TrueMark STI Select and Panels, allows simultaneous testing for various pathogens such as Chlamydia, Gonorrhea, and Herpes simplex virus, ensuring accurate and efficient diagnostics essential for disease management.
Thermo Fisher’s strategic acquisitions, including CorEvitas, bolster their diagnostic capabilities, particularly in data analysis.
With strong financial performance in Q1 2024, the company reaffirms its dedication to innovation and growth in healthcare.
Geographical Presence
Thermo Fisher Scientific, a prominent provider of laboratory equipment and services, maintains a robust global presence across over 50 countries.
Headquartered in Waltham, Massachusetts, its operations span North America, Europe, Asia-Pacific, Latin America, Africa, and the Middle East.
With strategically located facilities and distribution centers, Thermo Fisher effectively serves diverse markets, delivering cutting-edge scientific solutions to customers worldwide.
Recent Development
- In June 2024, Thermo Fisher Scientific Inc. launched the Thermo Scientific™ Stellar™ mass spectrometer (MS), which combines speed, sensitivity, and ease of use. This advancement speeds up translational omics research, helping researchers achieve breakthroughs more efficiently.
- In June 2024, Thermo Fisher Scientific Inc. launched a new ultra-cold facility in the EU, strengthening its clinical trial network to expedite advanced therapy development in Europe.
Bristol-Myers-Squibb
Company Overview
| Establishment Year | 1887 |
| Headquarter | Princeton, New Jersey, U.S. |
| Key Management | Chris Boerner (CEO) |
| Revenue (US$ Bn) | $ 45.01 B (2023) |
| Headcount | ~ 34,100 (2023) |
| Website | http://bms.com/ |
About Bristol Myers Squibb
Bristol Myers Squibb (BMS) has been actively enhancing its portfolio in the sexual health sector, focusing on innovative treatments and strategic expansions.
Recently, the company completed the acquisition of Karuna Therapeutics for $14 billion, gaining access to KarXT, a promising antipsychotic in advanced trials for schizophrenia and Alzheimer ‘s-related psychosis.
This acquisition aligns with BMS’s strategy to diversify and strengthen its pipeline. Additionally, BMS has been making significant strides in oncology, with the FDA approving its CAR T cell therapy, Breyanzi, for chronic lymphocytic leukemia and small lymphocytic lymphoma.
These developments highlight BMS’s commitment to expanding its therapeutic offerings and addressing unmet medical needs.
Geographical Presence
Bristol Myers Squibb (BMS) boasts a robust global presence across various regions. Headquartered in New York City, USA, the company operates extensively throughout North America, with additional offices and research centers in Canada.
In Europe, BMS has established regional headquarters in key cities like London and Paris, extending its reach into diverse markets such as Germany, Spain, and Italy.
Furthermore, the company has made significant strides in emerging markets, including Asia-Pacific and Latin America, by leveraging local operations and partnerships.
This expansive footprint underscores BMS’s dedication to advancing healthcare worldwide, aligning with its mission to transform patients’ lives through scientific innovation.
Recent Developments
- In March 2024, Bristol Myers Squibb finalized the purchase of Karuna Therapeutics, a company founded by PureTech, for $14 billion.
- In March 2024, Bristol Myers Squibb revealed that the FDA granted accelerated approval for Breyanzi, a CAR T cell therapy targeting CD19, to treat adults with relapsed or refractory CLL or SLL after at least two prior treatments.
Teva
Company Overview
| Establishment Year | 1901 |
| Headquarter | Tel Aviv, Israel |
| Key Management | Richard Francis (President and CEO) |
| Revenue (US$ Bn) | $ 15.8 Billion (2023) |
| Headcount | ~ 35,000 (2023) |
| Website | http://www.tevapharm.com/ |
About Teva Pharmaceuticals
Teva Pharmaceuticals is actively engaged in the sexual health sector, focusing on expanding and innovating its product offerings.
Recently, Teva completed the divestiture of its global women’s health business to CVC Capital Partners for $703 million.
This portfolio included products related to contraception, fertility, menopause, and osteoporosis, such as Ovaleap and Seasonique.
Additionally, Teva has been involved in strategic partnerships and product launches, including the approval of SIMLANDI, a high-concentration, citrate-free biosimilar to Humira, enhancing their biologics portfolio.
These moves reflect Teva’s strategy to streamline operations and focus on its core strengths in generic and specialty medicines.
Geographical Presence
Teva Pharmaceuticals, a global leader in generic and specialty medicines, has a strong presence across North America, Europe, Asia Pacific, Latin America, and the Middle East/Africa.
In North America, it operates manufacturing, research, and sales facilities, with European headquarters in Amsterdam overseeing activities continent-wide.
The company is expanding in Asia Pacific, focusing on Japan, China, and India. Latin America and the Middle East/Africa are also key regions, with offices, manufacturing, and distribution networks established. Teva is committed to providing high-quality, affordable medicines worldwide.
Recent Developments
- In April 2024, Teva Pharmaceuticals and Alvotech received FDA approval for SELARSDI injection, recognized as a biosimilar to Stelara.
- In October 2023, Sanofi and Teva Pharmaceuticals partnered on TEV’574, a TL1A inhibitor currently undergoing Phase IIb clinical trials for ulcerative colitis and Crohn’s disease, forms of inflammatory bowel disease (IBD).
Roche
Company Overview
| Establishment Year | 1896 |
| Headquarter | Basel, Switzerland |
| Key Management | Thomas Schinecker (CEO) |
| Revenue (US$ Bn) | $ 65.4 Billion (2022) |
| Headcount | ~ 122,000 (2022) |
| Website | http://www.roche.com/ |
About Roche
Roche has made notable advancements in sexual health, particularly in diagnostic testing for sexually transmitted infections (STIs).
Their innovative solutions include real-time PCR tests for STIs like Mycoplasma genitalium, Trichomonas vaginalis, and herpes simplex virus, crucial for early detection and treatment.
Recently, Roche has emphasized improving diagnostic capabilities with products like Elecsys® HIV duo, supporting comprehensive HIV testing.
Their focus on digital health and personalized medicine has led to advanced diagnostic tools, enhancing patient outcomes and clinical workflows.
These efforts demonstrate Roche’s commitment to using cutting-edge technology to address public health challenges in sexual health.
Geographical Presence
Roche, based in Basel, Switzerland, has a significant global presence spanning Europe, North America, Asia-Pacific, Latin America, Africa, and the Middle East.
Key centers in Switzerland, Germany, France, the UK, and the US drive research, manufacturing, and commercial activities.
In the Asia-Pacific region, including Japan, China, India, and Australia, Roche actively collaborates to address varied healthcare needs.
Extending into emerging markets in Latin America, Africa, and the Middle East, Roche aims to improve healthcare access and outcomes. This extensive presence underscores Roche’s dedication to advancing healthcare innovation worldwide.
Recent Developments
- In May 2024, Roche expanded its collaboration with Enable Injections to maximize Enable’s expertise and enFuse delivery technology.
- In March 2024, Roche partnered with PathAI, a top AI technology firm in pathology, to create AI-powered digital pathology algorithms for companion diagnostics.
Pfizer
Company Overview
| Establishment Year | 1849 |
| Headquarter | New York City, U.S. |
| Key Management | Albert Bourla (CEO) |
| Revenue (US$ Bn) | $ 58.5 Billion (2023) |
| Headcount | ~ 88,000 (2023) |
| Website | http://pfizer.com/ |
About Pfizer
Pfizer Inc. has achieved notable progress in sexual health, particularly with its innovative contraceptive solutions.
One recent advancement is the launch of Sayana® Press, an injectable contraceptive approved for self-administration in the UK.
Combining a long-acting contraceptive with a prefilled, single-use injection system, Sayana® Press offers women a convenient and discreet birth control option.
This reflects Pfizer’s commitment to improving global access to family planning, including collaborations with organizations like the Bill & Melinda Gates Foundation to distribute Sayana® Press in underserved areas.
Furthermore, Pfizer’s recent acquisition of Seagen is poised to strengthen its oncology and specialty medicine offerings significantly.
Geographical Presence
Pfizer Inc. maintains a vast geographical presence across more than 150 countries, strategically positioning itself to serve diverse markets globally.
With headquarters in New York City, USA, Pfizer operates extensively in North America, Europe, Asia-Pacific, Latin America, Africa, and the Middle East.
Its robust presence includes key markets such as the United States, Europe, Japan, China, Brazil, and India. Leveraging its innovative portfolio and expertise.
Pfizer addresses the healthcare needs of populations worldwide through research, development, manufacturing, and commercial operations.
By collaborating with local stakeholders, Pfizer aims to improve access to quality healthcare and make meaningful contributions to public health initiatives globally.
Recent Development
- In April 2024, Pfizer and Genmab A/S received FDA approval for the supplemental Biologics License Application (sBLA) for TIVDAK® (tisotumab vedotin-tftv). This grants full approval for the treatment of patients with recurrent or metastatic cervical cancer post-chemotherapy.
- In February 2024, Pfizer partnered with UT Southwestern Medical Center to develop RNA-enhanced delivery technologies for genetic medicine therapies.
Qiagen
Company Overview
| Establishment Year | 1984 |
| Headquarter | Venlo, Netherlands |
| Key Management | Thierry Bernard (CEO) |
| Revenue (US$ Bn) | $ 1.9 Billion (2023) |
| Headcount | ~ 5,967 (2023) |
| Website | http://qiagen.com/ |
About Qiagen
Qiagen NV has been actively enhancing its capabilities in sexual health diagnostics, notably with the development of diagnostic tools for sexually transmitted infections (STIs).
Recently, Qiagen obtained FDA clearance for its NeuMoDx CT/NG Assay 2.0, designed to detect Chlamydia trachomatis and Neisseria gonorrhoeae. Integrated with the NeuMoDx 96 and 288 Molecular Systems, this assay streamlines lab productivity by delivering rapid and precise results.
This FDA clearance expands Qiagen’s test menu in the U.S., complementing its range of CE-IVD-certified tests available in Europe and beyond.
Moreover, Qiagen’s focus on improving the accessibility and affordability of STI testing globally underscores its commitment to advancing sexual health diagnostics.
Geographical Presence
Qiagen NV, a prominent provider of molecular diagnostics and life sciences solutions, maintains a robust global presence.
Headquartered in Germantown, Maryland, USA, it serves North America’s diverse market. In Europe, key hubs in Germany and the UK facilitate research, development, and distribution.
Qiagen’s strategic locations in Shanghai, Tokyo, and other Asia-Pacific centers enable it to meet growing demands in the region.
Through partnerships in Latin America, Africa, and the Middle East, Qiagen extends its reach, reaffirming its commitment to advancing healthcare worldwide.
Recent Developments
- In May 2024, QIAGEN obtained FDA clearance for the clinical application of the QIAstat-Dx Respiratory Panel Plus syndromic test.
- In April 2024, Qiagen NV introduced the QIAseq xHYB Mycobacterium Tuberculosis Panel.
GE-Healthcare
Company Overview
| Establishment Year | 1994 |
| Headquarter | Chicago, Illinois, U.S. |
| Key Management | Peter Arduini (CEO) |
| Revenue (US$ Bn) | $ 19.5 Billion (2023) |
| Headcount | ~ 51,000 (2023) |
| Website | http://gehealthcare.com/ |
About GE Healthcare
GE Healthcare has made significant strides in sexual health, with a focus on improving diagnostics and expanding its technological portfolio.
Recently, it acquired BK Medical for $1.45 billion, bolstering its ultrasound capabilities and enhancing real-time surgical visualization.
Furthermore, GE Healthcare is investing in digital innovations, integrating AI and data analytics into its medical imaging systems to enhance diagnostic accuracy, especially in CT imaging for tumor and lesion detection.
These strategic actions align with GE Healthcare’s goal of delivering precise, connected, and patient-centered care, solidifying its leadership in healthcare technology.
Geographical Presence
GE Healthcare, based in Chicago, Illinois, maintains a strong global presence across North America, Europe, Asia-Pacific, Latin America, Africa, and the Middle East.
It strategically operates manufacturing facilities, research centers, and sales offices in key healthcare markets. Utilizing advanced medical technologies, GE Healthcare supports providers.
It improves patient outcomes in North America and Europe while collaborating with local stakeholders in other regions to address diverse healthcare needs and enhance access to quality care.
Through its extensive footprint and strategic partnerships, GE Healthcare is committed to advancing healthcare worldwide.
Recent Developments
- In May 2024, GE Healthcare collaborated with Medis Medical Imaging to improve accuracy in diagnosing and treating coronary artery disease.
- In February 2024, GE Healthcare and Biofourmis united to improve care continuity with safe, effective, and accessible home-based services, extending support beyond hospitals. This collaboration utilizes their expertise to scale and offer innovative home care solutions.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
